Search

Your search keyword '"Carrasquillo, Jorge"' showing total 703 results
Start Over Author "Carrasquillo, Jorge"
703 results on '"Carrasquillo, Jorge"'

152. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake

Author

Pandit-Taskar, Neeta, primary, O’Donoghue, Joseph A., additional, Ruan, Shutian, additional, Lyashchenko, Serge K., additional, Carrasquillo, Jorge A., additional, Heller, Glenn, additional, Martinez, Danny F., additional, Cheal, Sarah M., additional, Lewis, Jason S., additional, Fleisher, Martin, additional, Keppler, Jennifer S., additional, Reiter, Robert E., additional, Wu, Anna M., additional, Weber, Wolfgang A., additional, Scher, Howard I., additional, Larson, Steven M., additional, and Morris, Michael J., additional

Published
2016
Full Text
View/download PDF

153. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT

Author

Ulaner, Gary A., primary, Hyman, David M., additional, Ross, Dara S., additional, Corben, Adriana, additional, Chandarlapaty, Sarat, additional, Goldfarb, Shari, additional, McArthur, Heather, additional, Erinjeri, Joseph P., additional, Solomon, Stephen B., additional, Kolb, Hartmuth, additional, Lyashchenko, Serge K., additional, Lewis, Jason S., additional, and Carrasquillo, Jorge A., additional

Published
2016
Full Text
View/download PDF

155. A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with 89Zr-Df-IAB2M in metastatic prostate cancer (PCa).

Author

Morris, Michael J., primary, Martinez, Danny Francisco, additional, Durack, Jeremy C., additional, Slovin, Susan F., additional, Danila, Daniel Costin, additional, O' Donoghue, Joseph A., additional, Parada, Nicole Andrea, additional, Lyashchenko, Serge K., additional, Carrasquillo, Jorge A., additional, Ruan, Shutian, additional, Lewis, Jason Stuart, additional, Keppler, Jennifer, additional, Wu, Anna M., additional, Reuter, Victor E., additional, Weber, Wolfgang, additional, Scher, Howard I., additional, Larson, Steven M., additional, and Pandit-Taskar, Neeta, additional

Published
2016
Full Text
View/download PDF

157. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Author

Pandit-Taskar, Neeta, primary, O'Donoghue, Joseph A., additional, Durack, Jeremy C., additional, Lyashchenko, Serge K., additional, Cheal, Sarah M., additional, Beylergil, Volkan, additional, Lefkowitz, Robert A., additional, Carrasquillo, Jorge A., additional, Martinez, Danny F., additional, Fung, Alex Mak, additional, Solomon, Stephen B., additional, Gönen, Mithat, additional, Heller, Glenn, additional, Loda, Massimo, additional, Nanus, David M., additional, Tagawa, Scott T., additional, Feldman, Jarett L., additional, Osborne, Joseph R., additional, Lewis, Jason S., additional, Reuter, Victor E., additional, Weber, Wolfgang A., additional, Bander, Neil H., additional, Scher, Howard I., additional, Larson, Steven M., additional, and Morris, Michael J., additional

Published
2015
Full Text
View/download PDF

158. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates

Author

Cheal, Sarah M., primary, Xu, Hong, additional, Guo, Hong-fen, additional, Lee, Sang-gyu, additional, Punzalan, Blesida, additional, Chalasani, Sandhya, additional, Fung, Edward K., additional, Jungbluth, Achim, additional, Zanzonico, Pat B., additional, Carrasquillo, Jorge A., additional, O’Donoghue, Joseph, additional, Smith-Jones, Peter M., additional, Wittrup, K. Dane, additional, Cheung, Nai-Kong V., additional, and Larson, Steven M., additional

Published
2015
Full Text
View/download PDF

159. A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma.

Author

Kramer, Kim, Pandit‐Taskar, Neeta, Humm, John L., Zanzonico, Pat B., Haque, Sofia, Dunkel, Ira J., Wolden, Suzanne L., Donzelli, Maria, Goldman, Debra A., Lewis, Jason S., Lyashchenko, Serge K., Khakoo, Yasmin, Carrasquillo, Jorge A., Souweidane, Mark M., Greenfield, Jeffrey P., Lyden, David, De Braganca, Kevin D., Gilheeney, Stephen W., Larson, Steven M., and Cheung, Nai‐Kong V.

Published
2018
Full Text
View/download PDF

163. Gallbladder Paraganglioma Associated with SDHDMutation: a Potential Pitfall on 18F-FDOPA PET Imaging

Author

Abdul Sater, Zahraa, Jha, Abhishek, Mandl, Adel, Mangelen, Sheila, Carrasquillo, Jorge, Ling, Alexander, Gonzales, Melissa, Lopes Abath Neto, Osorio, Miettinen, Markku, Adams, Karen, Nockel, Pavel, Lakis, Mustapha, and Pacak, Karel

Abstract

A 36-year-old male patient initially presented with hypertension, tinnitus, bilateral carotid masses, a right jugular foramen, and a periaortic arch mass with an elevated plasma dopamine level but an otherwise normal biochemical profile. On surveillance MRI 4 years after initial presentation, he was found to have a 2.2-cm T2 hyperintense lesion with arterial enhancement adjacent to the gallbladder, which demonstrated avidity on 68Ga-DOTATATE PET/CT and retrospectively on 18F-FDOPA PET/CT but was non-avid on 18F-FDG PET/CT. Biochemical work-up including plasma catecholamines, metanephrines, and chromogranin A levels were found to be within normal limits. This lesion was surgically resected and was confirmed to be a paraganglioma (PGL) originating from the gallbladder wall on histopathology. Pheochromocytoma (PHEO) and PGL are rare tumors of the autonomic nervous system. Succinate dehydrogenase subunit D (SDHD) pathogenic variants of the succinate dehydrogenase complex are usually involved in parasympathetic, extra-adrenal, multifocal head, and neck PGLs. We report an unusual location of PGL in the gallbladder associated with SDHDmutation which could present as a potential pitfall on 18F-FDOPA PET/CT as its normal excretion occurs through biliary system and gallbladder. This case highlights the superiority of 68Ga-DOTATATE in comparison to 18F-FDOPA and 18F-FDG in the detection of SDHD-related parasympathetic PGL. ClinicalTrials.gov Identifier: NCT00004847.

Published
2019
Full Text
View/download PDF

165. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.

Author

Morris, Michael J., primary, Higano, Celestia S., additional, Scher, Howard I., additional, Sweeney, Christopher, additional, Antonarakis, Emmanuel S., additional, Shevrin, Daniel H., additional, Ryan, Charles J., additional, Loriot, Yohann, additional, Fizazi, Karim, additional, Pandit-Taskar, Neeta, additional, Garcia-Vargas, Jose E., additional, Lyseng, Kari, additional, Bloma, Marianne, additional, and Carrasquillo, Jorge A., additional

Published
2015
Full Text
View/download PDF

166. Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591.

Author

Feldman, Jarett L., primary, Morris, Michael J., additional, Martinez, Danny F., additional, Tagawa, Scott T., additional, Nanus, David M., additional, Solomon, Stephen Barnett, additional, Carrasquillo, Jorge A., additional, Reuter, Victor E., additional, Lewis, Jason Stuart, additional, O' Donoghue, Joseph A., additional, Slovin, Susan F., additional, Rathkopf, Dana E., additional, Gonen, Mithat, additional, Beylergil, Volkan, additional, Durack, Jeremy C., additional, Cheal, Sarah M., additional, Bander, Neil Harrison, additional, Scher, Howard I., additional, Larson, Steven M., additional, and Pandit-Taskar, Neeta, additional

Published
2015
Full Text
View/download PDF

167. STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC).

Author

Danila, Daniel Costin, primary, Fleisher, Martin, additional, Carrasquillo, Jorge A., additional, Gilbert, Houston, additional, Morris, Michael J., additional, Bellomo, Lawrence P, additional, Hendrikx, Petrus J, additional, Szafer-Glusman, Edith, additional, Herkal, Amrita, additional, Patel, Chintan, additional, Schreiber, Nicole A., additional, Curtis, Kristen Rebecca, additional, Maslyar, Daniel J., additional, Lemahieu, Vanessa, additional, Fine, Bernard M., additional, Mamounas, Michael J., additional, Ungewickell, Alexander Joachim, additional, Lackner, Mark R., additional, Scher, Howard I., additional, and Kabbarah, Omar, additional

Published
2015
Full Text
View/download PDF

168. Pathologic correlation of 89Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer.

Author

Morris, Michael J., primary, Solomon, Stephen Barnett, additional, Durack, Jeremy C., additional, O' Donoghue, Joseph A., additional, Lyashchenko, Serge K., additional, Shutian, Ruan, additional, Carrasquillo, Jorge A., additional, Lewis, Jason Stuart, additional, Martinez, Danny F., additional, Parada, Nicole A., additional, Keppler, Jennifer, additional, Wu, Anna, additional, Reuter, Victor E., additional, Weber, Wolfgang, additional, Scher, Howard I., additional, Larson, Steven M., additional, and Pandit-Taskar, Neeta, additional

Published
2015
Full Text
View/download PDF

169. Comparison of 6-[18F]-fluorodopamine positron emission tomography to [123I]-metaiodobenzylguanidine and [111In]-pentetreotide scintigraphy in the localization of non-metastatic and metastatic pheochromocytoma

Author

Ilias, Ioannis, Chen, Clara C., Carrasquillo, Jorge A., Whatley, Millie, Ling, Alexander, Lazúrová, Ivica, Adams, Karen T., Perera, Shiromi, and Pacak, Karel

Subjects
Diagnostic Imaging, Male, Fluorine Radioisotopes, Dopamine, Indium Radioisotopes, Pheochromocytoma, Article, Iodine Radioisotopes, 3-Iodobenzylguanidine, Positron-Emission Tomography, Humans, Female, Neoplasm Metastasis, Radiopharmaceuticals, Radionuclide Imaging, Retrospective Studies
Abstract

We compared functional imaging modalities including PET with 6-(18)F-fluorodopamine ((18)F-DA) with (123)I-metaiodobenzylguanidine ((123)I-MIBG) and somatostatin receptor scintigraphy (SRS) with (111)In-pentetreotide in nonmetastatic and metastatic pheochromocytoma (PHEO).We studied 25 men and 28 women (mean age +/- SD, 44.2 +/- 14.2 y) with biochemically proven nonmetastatic (n = 17) or metastatic (n = 36) PHEO. Evaluation included anatomic imaging with CT or MRI and functional imaging that included at least 2 nuclear medicine modalities: (18)F-DA PET, (123)I-MIBG scintigraphy, or SRS. Sensitivity of functional imaging versus anatomic imaging was assessed on a per-patient and a per-region basis.For this available cohort, on a per-patient basis overall sensitivity (combined for nonmetastatic and metastatic PHEO) was 90.2% for (18)F-DA PET, 76.0% for (123)I-MIBG scintigraphy, and 22.0% for SRS. On a per-region basis, overall sensitivity was 75.4% for (18)F-DA PET, 63.4% for (123)I-MIBG scintigraphy, and 64.0% for SRS.If available, (18)F-DA PET should be used in the evaluation of PHEO, because it is more sensitive than (123)I-MIBG scintigraphy or SRS. If (18)F-DA PET is not available, (123)I-MIBG scintigraphy (for nonmetastatic or adrenal PHEO) and SRS (for metastatic PHEO) should be the first alternative imaging methods to be used.

Published
2008

173. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.

Author

Pandit-Taskar, Neeta, O'Donoghue, Joseph A., Ruan, Shutian, Lyashchenko, Serge K., Carrasquillo, Jorge A., Heller, Glenn, Martinez, Danny F., Cheal, Sarah M., Lewis, Jason S., Fleisher, Martin, Keppler, Jennifer S., Reiter, Robert E., Wu, Anna M., Weber, Wolfgang A., Scher, Howard I., Larson, Steven M., and Morris, Michael J.

Published
2016
Full Text
View/download PDF

174. Abstract 2069: Initial PET imaging and pharmacokinetic results from a Phase I/II study of Zr-89-labeled anti-STEAP1 antibody in metastatic castrate-resistant prostate cancer (mCRPC) patients

Author

Carrasquillo, Jorge A., primary, Danila, Daniel C., additional, Beylergil, Volkan, additional, O'Donoghue, Joseph A., additional, Cheal, Sarah M., additional, Ruan, Shutian, additional, Pandit-Taskar, Neeta, additional, Fox, Josef J., additional, Fleming, Stephen E., additional, Zanzonico, Pat B., additional, Ragupathi, Govind, additional, Lyashchenko, Serge K., additional, William, Simon P., additional, Larson, Steven M., additional, Scher, Howard I., additional, Fine, Bernard M., additional, and Morris, Michael J., additional

Published
2014
Full Text
View/download PDF

176. Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).

Author

Abou-Alfa, Ghassan K., primary, Yen, Chia-Jui, additional, Carrasquillo, Jorge A., additional, Hsu, Chih-Hung, additional, Gansukh, Bolorsukh, additional, Ma, Jennifer, additional, Hollywood, Ellen, additional, Wan, Peter J, additional, Shao, Yu Yun, additional, Lin, Zhong-Zhe, additional, Frenette, Catherine, additional, O'Neil, Bert H., additional, Schwartz, Lawrence H., additional, Ohtomo, Toshihiko, additional, Tanaka, Takayoshi, additional, Chen, Ya-Chi, additional, Ukrainskyj, Stacey, additional, Saltz, Leonard, additional, Lee, Reuy-min, additional, and Cheng, Ann-Lii, additional

Published
2014
Full Text
View/download PDF

178. Radiation Safety Considerations for the Use of 223RaCl2 DE in Men with Castration-resistant Prostate Cancer

Author

Dauer, Lawrence T., primary, Williamson, Matthew J., additional, Humm, John, additional, O’Donoghue, Joseph, additional, Ghani, Rashid, additional, Awadallah, Robert, additional, Carrasquillo, Jorge, additional, Pandit-Taskar, Neeta, additional, Aksnes, Anne-Kirsti, additional, Biggin, Colin, additional, Reinton, Vigdis, additional, Morris, Michael, additional, and St. Germain, Jean, additional

Published
2014
Full Text
View/download PDF

181. Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.

Author

Morris, Michael J., primary, Pandit-Taskar, Neeta, additional, Tagawa, Scott T., additional, Nanus, David M., additional, Solomon, Stephen Barnett, additional, Carrasquillo, Jorge A., additional, Reuter, Victor E., additional, Lewis, Jason Stuart, additional, Beylergil, Volkan, additional, O' Donoghue, Joseph A., additional, Lyashchenko, Serge K., additional, Martinez, Danny F., additional, Curtis, Kristen Rebecca, additional, Durack, Jeremy C., additional, Cheal, Sarah M., additional, Bander, Neil Harrison, additional, Scher, Howard I., additional, and Larson, Steven M., additional

Published
2014
Full Text
View/download PDF

185. Prevotella spp y Porphyromonas spp en adultos jóvenes con enfermedad periodontal

Author

Muskus, Helena, Castro, Patricia, Márquez, Yoel, Cantillo, Richer, Carrasquillo, Jorge A., Muskus, Helena, Castro, Patricia, Márquez, Yoel, Cantillo, Richer, and Carrasquillo, Jorge A.

Abstract

Se ha establecido la relación causal de microorganismos en la enfermedad periodontal prestando interés en la investigación de especies bacterianas anaerobias, para determinar en cada región o país, el perfil epidemiológico asociado a la enfermedad periodontal, en Colombia se han realizado algunos esfuerzos aislados para lograr esto.

Published
2009

186. Split-Dose Technique for FDG PET/CT–guided Percutaneous Ablation: A Method to Facilitate Lesion Targeting and to Provide Immediate Assessment of Treatment Effectiveness

Author

Ryan, E. Ronan, primary, Sofocleous, Constantinos T., additional, Schöder, Heiko, additional, Carrasquillo, Jorge A., additional, Nehmeh, Sadek, additional, Larson, Steven M., additional, Thornton, Raymond, additional, Siegelbaum, Robert H., additional, Erinjeri, Joseph P., additional, and Solomon, Stephen B., additional

Published
2013
Full Text
View/download PDF

187. Repetitively dosed docetaxel and153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer

Author

Autio, Karen A., primary, Pandit-Taskar, Neeta, additional, Carrasquillo, Jorge A., additional, Stephenson, Ryan D., additional, Slovin, Susan F., additional, Rathkopf, Dana E., additional, Hong, Christina, additional, Heller, Glenn, additional, Scher, Howard I., additional, Larson, Steven M., additional, and Morris, Michael J., additional

Published
2013
Full Text
View/download PDF

188. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study.

Author

Morris, Michael J., primary, Hammers, Hans J., additional, Sweeney, Christopher, additional, Antonarakis, Emmanuel S., additional, Cho, Steve Y., additional, Pandit-Taskar, Neeta, additional, Jacene, Heather, additional, Bloma, Marianne, additional, Aksnes, Anne-Kirsti, additional, O'Bryan-Tear, C. Gillies, additional, and Carrasquillo, Jorge A., additional

Published
2013
Full Text
View/download PDF

190. Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).

Author

Morris, Michael J., primary, Pandit-Taskar, Neeta, additional, Carrasquillo, Jorge A., additional, O' Donoghue, Joseph A., additional, Humm, John, additional, Lyashchenko, Serge K., additional, Haupt, Eric C., additional, Bander, Neil Harrison, additional, Tagawa, Scott T., additional, Holland, Jason P., additional, Smith-Jones, Peter M., additional, Lewis, Jason Stuart, additional, Solomon, Stephen Barnett, additional, Scher, Howard I., additional, and Larson, Steven M., additional

Published
2013
Full Text
View/download PDF

191. Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial

Author

Divgi, Chaitanya R., primary, Uzzo, Robert G., additional, Gatsonis, Constantine, additional, Bartz, Roman, additional, Treutner, Silke, additional, Yu, Jian Qin, additional, Chen, David, additional, Carrasquillo, Jorge A., additional, Larson, Steven, additional, Bevan, Paul, additional, and Russo, Paul, additional

Published
2013
Full Text
View/download PDF

194. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity Y- or Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

Author

Cheal, Sarah, Xu, Hong, Guo, Hong-fen, Lee, Sang-gyu, Punzalan, Blesida, Chalasani, Sandhya, Fung, Edward, Jungbluth, Achim, Zanzonico, Pat, Carrasquillo, Jorge, O'Donoghue, Joseph, Smith-Jones, Peter, Wittrup, K., Cheung, Nai-Kong, and Larson, Steven

Subjects
COMPANION diagnostics, COLON cancer treatment, RADIOIMMUNOTHERAPY, BISPECIFIC antibodies, XENOGRAFTS
Abstract

Purpose: GPA33 is a colorectal cancer (CRC) antigen with unique retention properties after huA33-mediated tumor targeting. We tested a pretargeted radioimmunotherapy (PRIT) approach for CRC using a tetravalent bispecific antibody with dual specificity for GPA33 tumor antigen and DOTA-Bn-(radiolanthanide metal) complex. Methods: PRIT was optimized in vivo by titrating sequential intravenous doses of huA33-C825, the dextran-based clearing agent, and the C825 haptens Lu-or Y-DOTA-Bn in mice bearing the SW1222 subcutaneous (s.c.) CRC xenograft model. Results: Using optimized PRIT, therapeutic indices (TIs) for tumor radiation-absorbed dose of 73 (tumor/blood) and 12 (tumor/kidney) were achieved. Estimated absorbed doses (cGy/MBq) to tumor, blood, liver, spleen, and kidney for single-cycle PRIT were 65.8, 0.9 (TI 73), 6.3 (TI 10), 6.6 (TI 10), and 5.3 (TI 12), respectively. Two cycles of PRIT (66.6 or 111 MBq Lu-DOTA-Bn) were safe and effective, with a complete response of established s.c. tumors (100 - 700 mm) in nine of nine mice, with two mice alive without recurrence at >140 days. Tumor log kill in this model was estimated to be 2.1 - 3.0 based on time to 500-mm tumor recurrence. In addition, PRIT dosimetry/diagnosis was performed by PET imaging of the positron-emitting DOTA hapten Y-DOTA-Bn. Conclusion: We have developed anti-GPA33 PRIT as a triple-step theranostic strategy for preclinical detection, dosimetry, and safe targeted radiotherapy of established human colorectal mouse xenografts. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

199. Phase I trial of yttrium 90 resin microspheres in the treatment of colon cancer liver metastases progressing despite hepatic arterial as well as systemic chemotherapy: Preliminary results.

Author

Sofocleous, Constantinos T, primary, Kemeny, Nancy E., additional, Pandit-Taskar, Neeta, additional, Do, Kinh Gian, additional, Brody, Lynn A, additional, Garcia, Alessandra R, additional, Capanu, Marinela, additional, Chou, Joanne F., additional, Petre, Elena N, additional, and Carrasquillo, Jorge A., additional

Published
2012
Full Text
View/download PDF

200. Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Author

Jurcic, Joseph G., primary, Rosenblat, Todd L., additional, McDevitt, Michael R., additional, Pandit-Taskar, Neeta, additional, Carrasquillo, Jorge A., additional, Chanel, Suzanne M., additional, Zikaras, Kevin, additional, Frattini, Mark G., additional, Maslak, Peter G., additional, Cicic, Dragan, additional, Larson, Steven M., additional, and Scheinberg, David A., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results